Back to Search
Start Over
Arenavirus-Based Vectors Generate Robust SIV Immunity in Non-Human Primates.
- Source :
-
Vaccines [Vaccines (Basel)] 2024 Jul 02; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 02. - Publication Year :
- 2024
-
Abstract
- Arenavirus-based vectors are being investigated as therapeutic vaccine candidates with the potential to elicit robust CD8 T-cell responses. We compared the immunogenicity of replicating (artPICV and artLCMV) and non-replicating (rPICV and rLCMV) arenavirus-based vectors expressing simian immunodeficiency virus (SIV) Gag and Envelope (Env) immunogens in treatment-naïve non-human primates. Heterologous regimens with non-replicating and replicating vectors elicited more robust SIV IFN-γ responses than a homologous regimen, and replicating vectors elicited significantly higher cellular immunogenicity than non-replicating vectors. The heterologous regimen elicited high anti-Env antibody titers when administered intravenously, with replicating vectors inducing significantly higher titers than non-replicating vectors. Intramuscular immunization resulted in more durable antibody responses than intravenous immunization for both vector platforms, with no difference between the replicating and non-replicating vectors. Overall, both replicating and non-replicating arenavirus vectors generated robust T- and B-cell-mediated immunity to SIV antigens in treatment-naïve non-human primates, supporting further evaluation of these vectors in a clinical setting for HIV therapy.
Details
- Language :
- English
- ISSN :
- 2076-393X
- Volume :
- 12
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 39066373
- Full Text :
- https://doi.org/10.3390/vaccines12070735